Look Who's Attending | Last Chance to Save up to $400

Last Chance to Save up to $400 is This Friday, October 9th
Register Today
Be Sure to use code: D15172BLOG

  

Connect with hundreds of your colleagues this December in San Diego at the largest and most trusted Antibody Engineering & Therapeutics event to discover, engineer and develop novel and next generation antibody modalities across diverse disease indications. Included with your 4-day registration fee this year is a new 2-day Antibody-Drug Conjugate track that will showcase the latest progress and clinical updates from the most exciting ADC programs in development.

Secure your seat today to attend this year's meeting and access:
• 100+ speaker presentations covering critical scientific and development updates that can accelerate your antibody research, discovery efforts and clinical programs - download the agenda. 
• 50+ exhibitors to keep you on the pulse of evolving technologies
• 100+ scientific posters to give you first-hand updates on unpublished, peer-submitted research projects
• 700+ global antibody researchers for you to connect with onsite to forge successful scientific and business partnerships

A sample of the attending companies:
• Abbvie
• Albert Einstein College of Medicine
• Amgen
• Bayer Healthcare
• Biogen
• Boehringer Ingelheim
• Boston College
• Boston University
• Bramhill Biological Consulting
• Bristol Myers Squibb
• Celgene Corporation
• Covagen AG
• Daiichi Sankyo
• Dana Farber Cancer Institute
• Dartmouth College
• David Geffen School of Medicine at UCLA
• Development Center for Biotechnology
• Eli Lilly & Company
• EnGen Bio
• Esbatech A Novartis Company
• Genentech
• Genesun Biopharmaceutical      
• Genmab BV
• Genomics Inst of Novartis Research
• Genzyme Corporation
• Georgetown University
• GlaxoSmithKline
• Global Biological Standards Institute
• Imaginab
• Immunocore
• ImmunoGen
• Janssen
• Johnson & Johnson
• Jounce Therapeutics
• Kookmin University
• KTH Royal Institute of Technology
• Massachusetts Institute of Technology
• Maxcyte Inc
• MD Anderson Cancer Center
• MedImmune
• Meditope Biosciences
• Memorial Sloan Kettering Cancer Center
• Merck
• Merrimack Pharmaceuticals Inc
• National Cancer Center Hospital East
• National Cancer Institute NIH
• National Institute for Communicable Diseases
• National Research Council Canada
• Novartis
• Novo Nordisk   
• OMT Therapeutics
• Oslo University Hospital, Rikshospi
• Oxford University Kellogg College
• Panorama Research Institute
• Pfizer
• Queen Mary University of London
• Regeneron
• Research Corporation Technologies
• Roche
• Royal Institute of Technology (KTH)
• Sanofi
• Seattle Genetics
• Simon Fraser University
• Stanford University Medical Center
• Stanford University School of Medicine
• Taipei Medical University
• Takeda
• Tel Aviv University
• Teva Pharmaceuticals
• The Rockefeller University
• The Scripps Research Institute
• The University Of Tokyo
• Tokyo University of Pharmacy and Life Sciences• UCL Cancer Institute
• UMass Medical School
• Univ. of Texas MD Anderson Cancer Ct
• University of Cincinnati College of Medicine
• University of Pittsburgh Cancer Institute
• Vaccinex
• Yale School of Medicine and more!

Don't miss out! Join the growing list of attendees at the largest antibody engineering and therapeutics event in the industry! This Friday, October 9th is your last chance to take advantage of the early-bird savings of up to $400. Be sure to use code: D15172BLOG – Register here.

Best,
The Antibody & Protein Therapeutics – From Discovery to Production Team
@ibcusa
#AntibodyEng
http://futurebiopharma.blogspot.com/

Share this article with your social network, just click below to share now!

Share |

Antibody Repertoires - Past, Present and Future

IBC's Antibody Engineering & Therapeutics event taking place December 7-10 in San Diego is the #1 forum for academia and industry to connect for scientific exchange and networking in Antibody Engineerings & Therapeutics, Immunobiology and Next-Generation Binders. To give you a sneak peek at the high caliber of the content presented at the conference - we would like to give you FREE access to complete videos from some of the 2014 presentations.

We hope to see you in San Diego this December!

Share this article with your social network, just click below to share now!

Share |

New Development in Monoclonal Antibodies!

A recent development in monoclonal antibodies for Alzheimer's was announced in an article by FierceBiotech Research. Scientists at NYU Langone Medical Center's Center for Cognitive Neurology is conducting a study that suggests monoclonal antibodies designed to specifically target misfolding proteins in soluble, aggregated states, could be ideally used to treat neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, and Huntington's.

Monoclonal antibodies are now used for treatments of a wide array of diseases, especially cancer, autoimmune, and inflammatory diseases and the studies are only expanding. With the market for monoclonal antibodies exploding to an estimated $31.7 billion by 2017, don’t miss out on the opportunity to discover the future of antibody engineering at the upcoming IBC’s Antibody Engineering & Therapeutics event.

This is the most trusted antibody engineering event in the industry where you will not only connect with over 700 antibody industry experts, but also learn about the latest antibody science and applications to expand your pipeline of antibody therapeutics.

Hear from the below experts this December 7-10  in San Diego, CA to uncover more about monoclonal antibodies and recent developments for non-cancer and orphan indications.

• Trudi Veldman, Ph.D.., Senior Director Biologics Generation, AbbVie Bioresearch Center
• Patrik Maurer, Ph.D., Head Research and Preclinical Development, ESBATech, a Novartis Company, Switzerland
• Jos Raats, Ph.D., CEO, ModiQuest B.V., The Netherlands
• Mary Keir, Ph.D., Scientist, Immunology, Tissue Growth and Repair (ITGR), Diagnostic Discovery, Genentech, Inc.
• Ahuva Nissim, Ph.D., Reader in Antibody and Therapeutic Engineering, Biochemical Pharmacology, Queen Mary University, United Kingdom
• Ulrich Wuellner, Ph.D., Associate Director, Discovery Research, Covagen AG, Switzerland
• Chung-Ming Hsieh, D.SC., Associate Director, Biologics, AbbVie Bioresearch Center
• James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
• Bo Yu, Ph.D., Co-founder and CSO, Larix Bioscience, LLC
• Wendy Williams Ph.D., Scientist II, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
• Vaughn Smider, M.D., Ph.D., Assistant Professor, Department of Cell and Molecular Biology, The Scripps Research Institute
• Mark De Boer, Ph.D., CEO, Fast Forward Pharmaceuticals BV, The Netherlands
• Peter Ulrichts, Ph.D., Principal Scientist, arGEN-X BVBA, Belgium

Download the Brochure for the Full Session and Speaker Details.

Accelerate your antibody research, discovery efforts and clinical programs at the most comprehensive event for comparing and contrasting engineering, discovery and development strategies for different antibody modalities.

Plus, take advantage of an extra $100 off the current rate with code D15172BLOG - Register Now!

Share this article with your social network, just click below to share now!

Share |